Abstract 1894: Antitumor effects of everolimus, sorafenib, and axitinib in human renal cells carcinoma xenografts resistant to first line treatment by sunitinib

作者
Maria Serova,Célia Dos Santos,Annemilaï Tijeras‐Raballand,Maria-Eugenia Riveiro,Armand de Gramont,Sandrine Faivre,Éric Raymond
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:72 (8_Supplement): 1894-1894 被引量:1
标识
DOI:10.1158/1538-7445.am2012-1894
摘要

Abstract Background. Acquired resistance to sunitinib stands as a major clinical challenge in renal cell carcinoma. This study aimed to evaluate the antitumor effects of everolimus, sorafenib, and axitinib as second line treatment in renal cancer xenografts acquiring resistance to sunitinib. Materials and Methods: CAKI1 renal carcinoma cells (VHL+) were engrafted in nude mice and treated continuously with tumor-static doses of oral sunitinib (60 mg/kg) until progression (define as 100% increase tumor volume on 3 subsequent measurements). Mice that progressed were randomized to receive second line treatment with oral everolimus (2.5, 5, 10 and 20 mg/kg), sorafenib (60mg/kg), or axitinib (60mg/kg) for 3 weeks. Tumor responses and progression-free survival were calculated using Kaplan-Meier analysis. Tumors were analyzed by immunohistochemistry (IHC), Western blot, and q-RT-PCR. Results. First line sunitinib induced significant tumor growth delay compared with placebo (medians PFS: 50 and 17 days, respectively, p<0.0001) without toxicity. Tumors that progressed under sunitinib treatment showed higher mRNA levels of HIF-1α, VEGFA, CXCR4, and CA-IX as compared to tumors displaying response to sunitinib. An increase in CXCR4, vimentin, and HER3 protein expression was associated with sunitinib-resistance. No change in mouse CD31 mRNA was observed contrasting with an increased human CD31 mRNA expression in tumors developing resistance to sunitinib compared to sensitive tumors, suggesting that human cancer stem cells may dedifferentiate to gain angiogenic capacities at progression. Second line treatment with everolimus, sorafenib, and axitinib were well tolerated as defined by mouse weight, mortality, and behavior. Median PFS for 20 mg/kg everolimus was significantly higher than that of control group (13 and 5 days, respectively, p<0.001). Growth inhibition using 5 mg/kg/day everolimus was similar to that of axitinib. Doses >10mg/kg everolimus display higher effects on tumor growth than sorafenib and axitinib. Phospho-S6 expression was reduced in tumors treated with everolimus and axitinib but not with sorafenib, indicating that everolimus and axitinib inactivate the PI3k/AKT/mTOR signaling. IHC analysis of everolimus- and sorafenib-treated tumors showed no apoptosis, large hypoxic (by CA-IX staining) and necrotic areas associated, and a decreased number of tumor vessels (CD31 staining) compared to controls. Conversely, axitinib neither induce hypoxia nor necrosis in this model. Conclusions. This study shows that, using an appropriate tumor progression methodology, human tumor models can be used to evaluate first and second line treatment with targeted drugs. This setting also shows that xenograft models may allow testing molecular markers of response and resistance prior to clinical trials. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1894. doi:1538-7445.AM2012-1894

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
momo完成签到,获得积分10
1秒前
clcl完成签到,获得积分10
1秒前
xxj完成签到 ,获得积分10
1秒前
Cc完成签到 ,获得积分10
1秒前
陈艳林完成签到,获得积分10
1秒前
yuna完成签到,获得积分10
1秒前
L李发布了新的文献求助10
1秒前
十七关注了科研通微信公众号
1秒前
lnww完成签到,获得积分10
1秒前
pdf123完成签到,获得积分10
1秒前
炸鱼饼大人完成签到,获得积分10
2秒前
hivivian完成签到,获得积分10
2秒前
北顾发布了新的文献求助10
2秒前
gjy发布了新的文献求助10
2秒前
茸茸茸完成签到,获得积分10
2秒前
erpian完成签到,获得积分20
2秒前
芳芳芳发布了新的文献求助10
2秒前
夜休2024发布了新的文献求助10
3秒前
kyt完成签到,获得积分10
3秒前
风中的世平完成签到,获得积分10
3秒前
3秒前
xiepeijuan的应助被糕糕采纳,获得20
4秒前
齐777完成签到 ,获得积分10
4秒前
csjlpp完成签到,获得积分10
4秒前
我是老大的应助被哇塞的晚秋采纳,获得10
4秒前
SciGPT的应助被YPHCC采纳,获得30
4秒前
Janely完成签到,获得积分10
4秒前
小繁发布了新的文献求助10
4秒前
LC完成签到,获得积分10
4秒前
Menand完成签到,获得积分10
5秒前
科研狗完成签到,获得积分10
5秒前
HeHe发布了新的文献求助10
5秒前
5秒前
科研小白完成签到,获得积分10
5秒前
春申君完成签到,获得积分10
5秒前
5秒前
HAO完成签到,获得积分10
5秒前
jiabu完成签到,获得积分10
5秒前
5秒前
菲菲完成签到 ,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042